Form 8-K - Current report:
SEC Accession No. 0001193125-25-071428
Filing Date
2025-04-02
Accepted
2025-04-02 17:05:17
Documents
15
Period of Report
2025-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d906862d8k.htm   iXBRL 8-K 26741
2 EX-10.1 d906862dex101.htm EX-10.1 10288
  Complete submission text file 0001193125-25-071428.txt   193525

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA grtx-20250331.xsd EX-101.SCH 3220
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE grtx-20250331_def.xml EX-101.DEF 13335
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE grtx-20250331_lab.xml EX-101.LAB 21784
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grtx-20250331_pre.xml EX-101.PRE 14091
18 EXTRACTED XBRL INSTANCE DOCUMENT d906862d8k_htm.xml XML 5526
Mailing Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

EIN.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39114 | Film No.: 25805901
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)